NCT04037254 2026-03-16
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
Clinical Trials
21 trialsNCT03009981 2025-12-18
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Phase 3 Completed
NCT07127315 2025-08-17
Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
Helwan University
Completed
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT04992026 2024-12-05
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT00914823 2024-07-31
Kisspeptin Administration in the Adult
Massachusetts General Hospital
Phase 1 Completed
NCT00099086 2024-01-31
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00587431 2023-11-07
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03279250 2022-08-10
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02229734 2021-06-04
FASTR-2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Completed
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02475057 2019-06-12
Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
Rabin Medical Center
Phase 4 Completed
NCT01638247 2018-09-19
MALE
GBG Forschungs GmbH
Phase 3 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT02483767 2017-10-17
POF
Peking Union Medical College Hospital
Phase 3 Completed
NCT00006359 2016-07-18
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00586898 2016-03-25
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01674270 2015-12-22
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
University Health Network, Toronto
Phase 2 Completed
NCT02086279 2014-11-25
AMH Levels Change During Treatment With GnRh Agonist
University Magna Graecia
Phase NA Completed
NCT01581944 2012-04-20
Gonadotropin-releasing Hormone Agonist Prior to Myomectomy
Mt. Hope Maternity Hospital
Phase 3 Completed
NCT00746031 2010-10-25
Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids
University of Edinburgh
Phase 4 Completed